For more than two decades, Matt Kaeberlein studied the biology of aging from behind a lab bench, publishing hundreds of papers and building one of the most respected research programs in the field of geroscience. Now, the former University of Washington professor has turned himself into the experiment — and his personal longevity protocol reveals just how much the science of aging has matured from theoretical curiosity to actionable daily practice.
Kaeberlein, who left his tenured position in 2023 amid a dispute with the university, has emerged as one of the most influential voices in translational aging research. His approach is notable not for exotic interventions or bleeding-edge therapeutics, but for its disciplined reliance on fundamentals — the unsexy, evidence-backed habits that most people know about but few execute consistently. As he detailed in a recent interview with Business Insider, his regimen for 2026 is built around exercise, sleep, nutrition, and stress management, with a handful of supplements and one prescription drug added to the mix.
Exercise as the Cornerstone: Why the Data Points to Movement Above All Else
At the foundation of Kaeberlein’s protocol sits exercise — and not in a casual, take-a-walk-around-the-block sense. He has described physical activity as the single most impactful intervention available for extending both lifespan and healthspan, a position supported by a growing body of epidemiological and mechanistic research. His routine includes a combination of cardiovascular training and resistance work, reflecting the emerging consensus among longevity researchers that both modalities are essential. Cardiorespiratory fitness, as measured by VO2 max, has been shown in large observational studies to be among the strongest predictors of all-cause mortality, and Kaeberlein takes this data seriously.
His strength training component targets the preservation of muscle mass and function — a critical concern as sarcopenia, the age-related loss of skeletal muscle, accelerates frailty and disability in later decades. Kaeberlein has noted that resistance exercise activates molecular pathways, including mTOR signaling, that are central to his academic research on aging biology. The irony is not lost on him: the very pathway he spent years studying in yeast and mice is one he now deliberately modulates through barbells and dumbbells. He aims for consistency over intensity, training multiple days per week with a program designed to be sustainable across years and decades rather than optimized for short-term performance peaks.
Sleep and Stress: The Undervalued Pillars of Biological Aging
Kaeberlein has been vocal about the role of sleep in the aging process, placing it alongside exercise as a non-negotiable element of his routine. He prioritizes seven to eight hours per night and has spoken about the importance of sleep architecture — not just duration, but the quality and composition of sleep stages. Research from institutions including Stanford and Harvard has linked chronic sleep deprivation to accelerated epigenetic aging, impaired immune function, increased systemic inflammation, and elevated risk of neurodegenerative disease. For Kaeberlein, optimizing sleep is not a luxury but a biological imperative, and he structures his evening routine around practices that support circadian rhythm alignment, including limiting blue light exposure and maintaining consistent sleep and wake times.
Stress management rounds out what Kaeberlein considers the foundational triad. Chronic psychological stress drives sustained activation of the hypothalamic-pituitary-adrenal axis, elevating cortisol levels and promoting a pro-inflammatory state that accelerates multiple hallmarks of aging. Kaeberlein has discussed his use of mindfulness practices and deliberate recovery periods, though he tends to avoid prescribing specific meditation techniques, instead emphasizing the importance of finding an approach that an individual will actually maintain. His pragmatism on this point is characteristic: he is less interested in what is theoretically optimal than in what real people will do consistently over time, a philosophy that sets him apart from some of the more prescriptive voices in the longevity space.
Nutrition Without Dogma: A Flexible Approach to Dietary Intervention
On the nutrition front, Kaeberlein’s approach is deliberately non-dogmatic. He avoids aligning himself with any single dietary ideology — neither strict ketogenic, nor carnivore, nor vegan — instead focusing on broad principles supported by the evidence base. According to his comments reported by Business Insider, he emphasizes adequate protein intake to support muscle protein synthesis, particularly important given his resistance training regimen. He also prioritizes whole, minimally processed foods and limits added sugars and ultra-processed products, which have been linked in multiple large cohort studies to increased cardiovascular disease risk, metabolic dysfunction, and premature mortality.
Kaeberlein has expressed skepticism about aggressive caloric restriction in humans, despite the robust evidence for its lifespan-extending effects in model organisms ranging from yeast to primates. His reasoning is practical: the degree of restriction required to replicate animal study results would be unsustainable and potentially counterproductive for most people, particularly those engaged in regular intense exercise. Instead, he favors a moderate approach that avoids chronic overconsumption without imposing the misery of severe energy deficit. He has also been measured in his assessment of intermittent fasting, acknowledging some promising data while noting that the human evidence remains mixed and that adherence varies enormously across individuals.
Rapamycin: The Prescription Drug at the Center of Kaeberlein’s Research Legacy
Perhaps the most notable element of Kaeberlein’s personal protocol is his use of rapamycin, an immunosuppressant drug originally developed to prevent organ transplant rejection. Kaeberlein’s academic career was deeply intertwined with research on rapamycin and the mTOR pathway it inhibits. The drug has extended lifespan in every organism in which it has been tested, including mice, where it has shown effects even when administered late in life. Kaeberlein co-founded the Dog Aging Project, which among other studies investigated rapamycin’s effects on cardiac function in companion dogs — a translational step between rodent models and human application.
He takes rapamycin at a low, intermittent dose — a protocol designed to capture the drug’s potential geroprotective benefits while minimizing the immunosuppressive side effects associated with the higher, continuous dosing used in transplant medicine. This pulsed dosing strategy is based on preclinical data suggesting that intermittent mTOR inhibition can enhance rather than suppress certain aspects of immune function, particularly in older individuals. Kaeberlein has been transparent about the fact that definitive human longevity data for rapamycin does not yet exist, but he has argued that the totality of evidence — spanning multiple species and decades of mechanistic research — justifies personal use under medical supervision. His willingness to take the drug himself lends credibility to his advocacy, though he is careful to note that he is not recommending it for the general public without physician guidance.
Supplements and the Evidence Threshold for Personal Use
Beyond rapamycin, Kaeberlein’s supplement stack is relatively restrained compared to some prominent longevity enthusiasts. He has mentioned taking vitamin D, which is supported by substantial evidence for bone health and immune function, and which a significant portion of the population is deficient in, particularly at northern latitudes. He has also discussed omega-3 fatty acids, citing their anti-inflammatory properties and cardiovascular benefits. Notably absent from his regimen are many of the more hyped longevity supplements, including NMN and NR — precursors to NAD+ that have generated enormous consumer interest but whose human efficacy data Kaeberlein has publicly characterized as insufficient.
This selective approach to supplementation reflects a broader philosophy that Kaeberlein has articulated repeatedly in public appearances and on social media: the threshold of evidence required to justify a personal intervention should be proportional to its cost, risk, and inconvenience. Exercise, sleep, and nutrition carry virtually no risk and enormous potential benefit, so the evidence bar is low. A prescription drug like rapamycin carries more risk, so the evidence bar is higher — but in Kaeberlein’s assessment, the preclinical data clears it. Supplements with limited human data and meaningful cost, meanwhile, often fail to meet his standard, regardless of how compelling the mechanistic story may be.
From the Ivory Tower to the Public Square: Kaeberlein’s Evolving Role
Kaeberlein’s departure from the University of Washington was acrimonious, involving allegations that the university had retaliated against him for whistleblowing activities. He has since channeled his energy into public science communication, building a substantial following on social media platforms where he regularly engages with both scientific peers and lay audiences. His Substack newsletter and frequent appearances on health-focused podcasts have made him one of the most accessible translators of aging biology for non-specialist audiences. This public-facing role has not been without controversy — some academic colleagues have questioned whether the transition from researcher to influencer risks oversimplifying complex science — but Kaeberlein has argued that the field’s failure to communicate effectively with the public has been one of its greatest shortcomings.
His personal protocol, as outlined in his Business Insider feature, serves as both a practical guide and a philosophical statement. It says that the most important things you can do to age well are not expensive, not exotic, and not secret. They are, in fact, boring — and that is precisely the point. The gap between what the science supports and what most people actually do remains enormous, and Kaeberlein’s central message is that closing that gap matters far more than chasing the next breakthrough molecule or biohacking gadget.
What the Kaeberlein Protocol Tells Us About the State of Aging Science
The fact that one of the world’s foremost aging researchers has built his personal longevity strategy primarily around exercise, sleep, diet, and stress management — with a single well-studied drug and a handful of basic supplements — is itself a powerful signal about where the field stands. It suggests that while the molecular biology of aging has advanced dramatically, the translation of that knowledge into novel human interventions remains in its early stages. The most evidence-backed tools available today are the same ones that physicians have recommended for generations, now buttressed by a far deeper understanding of the mechanisms through which they operate.
For industry insiders watching the longevity space — investors, drug developers, clinicians, and entrepreneurs — Kaeberlein’s protocol is a reminder that the market opportunity in aging is not only about novel therapeutics. It is also about behavior change, adherence technology, and the systems that help people consistently execute the fundamentals. The scientist who spent his career searching for the molecular keys to extended life has concluded, at least for now, that the most powerful tools are hiding in plain sight. The challenge is not discovery. It is execution.
WebProNews is an iEntry Publication